🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06900010
Recruiting Phase 2

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

NCT06900010 · tracked via the Priya Life Science China tracker
Sponsor
Shandong First Medical University
Phase
Phase 2
Started
2025-04-22
Last updated
2026-04-06

Condition(s) studied

Autoimmune Bullous Disease

Investigational drug(s) / intervention(s)

CM336 Injection

CM336 Injection: subcutaneous CM336 administration

Study summary

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * 1\. Confirmed diagnosis of autoimmune bullous disease; * 2\. Age ≥18 years, regardless of gender; * 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements. Exclusion Criteria: * 1\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation; * 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy; * 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336; * 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dermatology Hospital Affiliated to Shandong First Medical University Jinan China Recruiting

More Shandong First Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06900010 on ClinicalTrials.gov ↗ ← All trials in China